In vivo etoposide-resistant C6 glioma cell line: Significance of altered DNA topoisomerase II activity in multi-drug resistance

Journal of Neuro-Oncology

Volumn 36, Issue 1, 1998, Pages 41-53

  Taki, Takuyu ^a,b   Ohnishi, Takanori ^a   Arita, Norio ^a   Hiraga, Shoju ^a   Hayakawa, Toru ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

DNA topoisomerase II; Etoposide; Glioma

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MESSENGER RNA; NIMUSTINE; VINBLASTINE; VINCRISTINE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; CROSS RESISTANCE; DNA BINDING; ENZYME ACTIVITY; GENE EXPRESSION; GLIOMA CELL; MULTIDRUG RESISTANCE; NONHUMAN; NORTHERN BLOTTING; PHENOTYPE; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; BLOTTING, WESTERN; CELL NUCLEUS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETOPOSIDE; GLIOMA; ISOENZYMES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; P-GLYCOPROTEIN; RATS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0031777053     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005718912236     Document Type: Article

References (60)

1. Beck WT: Unknotting the complexities of multidrug resistance: the involvement of D NA topoisomerase in drug action and resistance. J Natl Cancer Inst 81: 1683-1685, 1989
2. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989
3. Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M, Blick M: Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem 264: 16411-16420, 1989
4. Zwelling LA: DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metastasis Rev 4: 263-276, 1985
5. Osheroff N: Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28: 6157-6160, 1989
6. Robinson MJ, Osheroff N: Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4′-(9-acridinylamino) methanesulfon-m-anisidide. Biochemistry 29: 2511-2515, 1990
7. Zwelling LA: Topoisomerase II as a target of antileukemia drugs: A review of controversial areas. Hematol Pathol 3: 101-112, 1989
8. Riordan JR, Deuchars K, Kartner N, Alon N, Trent H, Ling V: Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316: 817-819, 1985
9. Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Rominson IB : Internal duplication and homology with bacterial transport proteins in the mdr1 gene from multidrug-resistant human cells. Cell 47: 381-389, 1986
10. Gros P, Ben Neriah Y, Croop JM, Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728-731, 1986
11. Gros P, Croop J, Housman D : Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47: 371-380, 1986
12. Scotto KW, Biedler JL, Melera PW: Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 232: 751-755, 1986
13. Shen DW, Fojo A, Rominson IB, Chin JE, Soffir R, Pastan I, Gottesman MM: Multidrug-resistance of DNA-mediated transformants is linked to transfer of the human mdrI gene. Mol Cell Biol 6: 4039-4044, 1986
14. Van der Bliek A, Van der Velde-Koerts T, Ling V, Borst P: Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line. Mol Cell Biol 6: 1671-1678, 1986
15. Croop JM, Guikd BC, Gros P, Housman DE: Genetics of multidrug-resistance: relationship of a cloned gene to the complete multidrug-resistance phenotype. Cancer Res 47: 5982-5988, 1987
16. Sugimoto Y, Tsuruo T: DNA-mediated transfer and cloning of a human multidrug-resistant gene of an adryamycin-resistant myelogenous leukemia K562. Cancer Res 47: 2620-2625, 1987
17. Ueda K, Pastan I, Gottesman MM: Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 262: 17432-17436, 1987
18. Deuchars KL, Du RP, Naik M, Evernden-Porelle D, Kartner N, Van der Bliek AM, Ling V: Expression of hamster P-glycoprotein and multidrug resistance in DNA -mediated transformants of mouse LTA cells. Mol Cell Biol 7: 718-724, 1987
19. Raymond M, Rose E, Housman DE, Gros P: Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistance cells. Mol Cell Biol 10: 1642-1651, 1990
20. Silverman JA, Raunio H, Gant TW, Thorgeirsson SS: Cloning and characterization of a member of the rat multidrug resistance (mdr) gene family. Gene 106: 229-236, 1991
21. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992
22. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM: Pharmacological, molecular, and cytogenetic analysis of 'atypical' multidrug-resistant human leukemic cells. Cancer Res 47: 5455-5460, 1987
23. Danks MK, Yalowich JC, Beck WT: Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM- 26). Cancer Res 47: 1297-1301, 1987
24. RappaG, Lorico A, Sartorelli AC: Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). Int J Cancer 51: 780-787, 1992
25. Friche E, Danks MK, Schmidt CA, Beck WT: Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res 51: 4213-4218, 1991
26. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M: Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51: 3951-3957, 1991
27. Fernandes DJ, Danks MK, Beck WT: Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry 29: 4235-4241, 1990
28. Feldhoff PW, Mirski SEL, Cole SPC, Sullivan DM: Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell Lung cancer cell line. Cancer Res 54: 756-762, 1994
29. Madajewicz S, Chowhan N, Iliya A, Roque C, Beaton R, Davis R, Fertman S, Meek A, Alvarez O, Pampati M, Tyson G: Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors. Cancer 67: 2844-2849, 1991
30. Chamberlain MC: Recurrent brainstem gliomas treated with oral VP-16. J Neuro-Oncol 15: 133-139, 1993
31. Tsutsui K, Tsutsui K, Sakurai H, ShohmoriT, Oda T: Levels of topoisomerase II and DNA polymerase alpha are regulated independently in developing neuronal nuclei. Biochem Biophys Res Commu 138: 1116-1122, 1986
32. Tsutsui K, Tsutsui K, Muller MT: The nuclear scaffold exhibits DNA-binding sites selective for supercoiled DNA. J Biol Chem 263: 7235-7241, 1988
33. Oegema TJ, Carpenter BJ, Thompson RJ: Fluorometric determination of DNA in cartilage of various species. J Orthop Res 1: 345-351, 1984
34. Badenoch DF, Fowler CG, Evans PR, Lowrey PA: DNA content of human semen - an objective measurement of sperm density. Br J Urol 57: 230-232, 1985
35. Gillery P, Bonnet A, Borel JP: A fluorometric deoxyribonucleic acid assay for tridimensional lattice cultures of fibroblasts. Anal Biochem 210: 374-377, 1993
36. Farina P, Marzillo G, D'Incalci M: High-performance liquid chromatography determination of 4′-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma. J Chromatogr 222: 141-145, 1981
37. Hersh MR, Ludden TM: High-performance liquid chromatographic assay for etoposide in human plasma. J Pharm Sci 75: 815-817, 1986
38. Adolph KW, Chang SM, Paulson JR, Laemmli UK: Isolation of a protein scaffold from mitotic HeLa cell chromosomes. Proc Natl Acad Sci USA 11: 4937-4941, 1977
39. Earnshaw WC, Laemmli UK: Architecture of metaphase chromosomes and chromosome scaffolds. J Cell Biol 96:84-93, 1983
40. Deffie AM, McPherson JP, Gupta RS, Hedley DW, Goldenberg GJ: Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II. Biochem Cell Biol 70: 354-364, 1992
41. DeJong S, Zijlstra JG, de VE, Mulder NH: Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304-309, 1990
42. Glisson B, Gupta R, Smallwood KS, Ross W: Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res 46: 1934-1938, 1986
43. Pommmier Y, Kerrigan D, Schwartz RE, Swack JA, McCurdy A: Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075-3081, 1986
44. Estey EH, Silberman L, Beran M, Andersson BS, Zwelling LA: The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4′-(9-acridinylamino)methanesulfon-m-anisidide (m-AMA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem Biophys Res Commun 144: 787-793, 1987
45. Cockerill PN, Garrard WT: Chromosomal loop anchorage of the kappa immunoglobulin gene occurs next to the enhancer in a region containing topoisomerase II site. Cell 44: 273-282, 1986
46. Gasser SM, Laemmli UK: Cohabitation of scaffold binding regions with upstream/enhancer elements of three developmentally regulated genes of D. melanogaster. Cell 46: 521-530, 1986
47. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK: Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 86: 9431-9435, 1989
48. Tsutsui K, Tsutsui K, Okada S, Watanabe M, Shohmori T, Seki S, Inoue Y: Molecular cloning of partial cDNA for rat DNA topoisomerase II isoforms and their differential expression in brain development. J Biol Chem 268: 19076-19083, 1993
49. Hsiang YH, Wu HY, Liu LF: Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48: 3230-3235, 1988
50. Wang JC: DNA topoisomerases. Ann Rev Biochem 54: 665-697, 1985
51. Charros M, Hancock R: DNA topoisomerase II is required for formation of mitotic chromosomes in Chinese hamster ovary cells: studies using the inhibitor 4′-demethylepipodophyllotoxin 9-(4,6-O-thenylidene-beta-D-glucopyranoside). Biochemistry 29: 9531-9537, 1990
52. Woessner RD, Chung TD, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH, Johnson RK: Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II. Cancer Res 50: 2901-2908, 1990
53. Wood ER, Earnshaw WC: Mitotic chromatin condensation in vitro using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase II. J Cell Biol 111: 2839-2850, 1990
54. Adachi Y, Luke M, Laemmli U K: Chromo some assembly in vitro: topoisomerase II is required for condensation. Cell 64: 137-148, 1991
55. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH: Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Diff 2: 209-214, 1991
56. Negri C, Chiesa R, Cerino A, Bestagno M, Sala C, Zini N, Maraldi NM, Astaldi RG: Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp Cell Res 200: 452-459, 1992
57. Zini N, Martelli AM, Sabatelli P, Santi S, Negri C, Astaldi RG, Maraldi NM: The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant. Exp Cell Res 200:460-466, 1992
58. Ng WF, Sarangi F, Zastawny RL, Veinot DL, Ling V: Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 9: 1224-1232, 1989
59. Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM: Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 51: 5275-5283, 1991
60. Tan KB, Mattern MR, Boyce RA, Schein PS: Unique sensitivity of nitrogen mustard-resistant human Burkitt lymphoma cells to novobiocin. Biochem Pharmacol 37: 4411-4413, 1988